FDA - HealthQuill

The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults.

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

by HealthQuill
April 4, 2024
0 Comments

The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and substantial risk” of illness or injury.

Drugs Medical Pharma

FDA attempts a second time to ban electrical stimulation devices

HQ Team March 26, 2024: The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and.

by HealthQuill
March 26, 2024
0 Comments

The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the brain and nervous system in children — the regulator’s first ever for the disorder.

Drugs Health Pharma

FDA green lights first-ever therapy for rare genetic disease in kids

HQ Team March 19, 2023: The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the.

by HealthQuill
March 19, 2024
0 Comments

Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.

Drugs Health Pharma

Pfizer says trials on lymphoma drug ‘positive,’ extends life of patients

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

by HealthQuill
March 12, 2024
0 Comments

The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus on medicines that are likely to predict a clinical benefit.

Drugs Health Pharma

FDA issues revised drug guidelines for early Alzheimer’s disease

HQ Team March 12, 2024: The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus.

by HealthQuill
March 12, 2024
0 Comments

The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute leukaemia.

Drugs Health Pharma

Pfizer’s pediatric leukaemia drug gets regulator FDA’s green light

HQ Team March 7, 2024: The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute.

by HealthQuill
March 7, 2024
0 Comments

Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a heart drug for $310 million to expand its cardiology portfolio.

Drugs Health Pharma

Bayer acquires marketing rights for heart drug in Europe for $310 million

HQ Team March 4, 2024: Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a.

by HealthQuill
March 4, 2024
0 Comments

Pfizer Inc., a US pharmaceutical and biotechnology corporation, announced its single dose of respiratory syncytial virus (RSV) vaccine would maintain protection from the disease through to a second season.

Drugs Health Pharma

Pfizer says RSV vaccine can ensure protection into second season

HQ Team March 1, 2024: Pfizer Inc., a US pharmaceutical and biotechnology corporation, announced its single dose of respiratory syncytial virus (RSV) vaccine.

by HealthQuill
March 1, 2024
0 Comments

An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children and adults in case of accidental exposure, according to a study funded by the US medical research agency.

Drugs Health Pharma

Omalizumab or Xolair can lower risk of food allergies in kids, adults: NIH

HQ Team February 26, 2024: An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children.